Clinical trials are an important way to improve treatment for people with cancer. While most are continuing during the COVID-19 pandemic, the period of time that clinical trials are available and recruiting may change quickly. If you would like to get involved in a clinical trial, speak to your treatment team or the health service where the clinical trial is being undertaken, to confirm it is open and appropriate for you. For cancer information and support, call Cancer Council's experienced cancer nurses on 13 11 20 Monday to Friday from 9am-5pm.

Menin Umbrella : A Phase 1b Study of JNJ-75276617 in Combination With AML Directed Therapies for Participants With Acute Myeloid Leukemia Harboring KMT2A or NPM1 Alterations

Male or<br/>FemaleGender Male or
Female

RecruitingStatus Recruiting

Systemic<br/>Therapy TrialTypeSystemic
Therapy Trial

OnePhase One

18+Age Over 18

Blood<br/>CancersCancer LocationBlood
Cancers

Systemic therapy | Blood / Myeloma / LymphomaAcute Myeloid Leukaemia

Trial Overview Read MoreRead more

This phase I study is seeking to determine the effectiveness and appropriate dose level of a new drug (JNJ-75276617) in combination with other drugs (venetoclax and/or azacitidine) in people with acute myeloid leukaemia.
 

This trial is treating patients with acute myeloid leukaemia.

This is a systemic therapy trial.

You may be able to join this trial if:

  • You are able to swallow medication by mouth.
  • You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
  • You have had treatment, but your cancer has come back.

You may be excluded from this trial if:

  • You have a certain disease or psychological condition.
  • You have had certain treatments, surgical procedures or drugs.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

A Phase 1b Study of JNJ-75276617 in Combination With AML Directed Therapies for Participants With Acute Myeloid Leukemia Harboring KMT2A or NPM1 Alterations

Commercial Sponsor

Janssen Research & Development, LLC

Summary

This study has two phases: dose selection and dose expansion. In the dose selection phase, participants with relapsed or refractor acute myeloid leukaemia (AML) with either NPM1 or KMT2A alterations will receive JNJ-75276617 in combination with venetoclax and/ or azacitidine to select the recommended phase 2 dose (RP2D) of JNJ-75276617 in combination with venetoclax and/or azacitidne. There will be three cohorts. Cohort A1 will receive JNJ-75276617 (orally) + venetoclax (orally). Cohort A2 will receive JNJ-75276617 (orally) + azacitidine (intravenously). Cohort A3 will receive JNJ-75276617 (orally) + venetoclax (orally) + azacitidine (intravenously). In the dose expansion phase of the study, participants will receive JNJ-75276617 in combination with AML directed therapies (venetoclax and/or azacitidine) at the RP2D(s).

Recruiting Hospitals Read MoreRead more

PCCTU (Parkville Cancer Clinical Trials Unit) *
Parkville
Jessica Ahern
PCCTU.HaemA@petermac.org

Trial Overview: General information about a clinical trial. This section provides an overview of who might be able to join this trial and what type of treatment is involved.

Next